Aug 1, 1979

Prognostic factors in metastatic and hormonally unresponsive carcinoma of the prostate

W R BerryD F Paulson


Eighty-eight patients with hormone-resistant Stage IV prostate cancer were treated with a five-drug chemotherapy program. Patient demographic data, prior therapy, symptoms, extent of disease, and laboratory studies were analyzed statistically to evaluate the association of these parameters with survival from the onset of chemotherapy. Factors associated with short survival included age greater than 65, severe bone pain, poor performance status, presence of soft tissue metastases, anemia, elevation of serum LDH, SGOT, alkaline and acid phosphatases, and prolactin, and hypoalbuminemia. Race, stage at initial diagnosis, prior radiation therapy, prior orchiectomy, and elevation of CEA had no prognostic association. We suggest that clinical trials of new therapies of hormone-resistant prostate cancer take into account the presence of these prognostic factors in the analysis of the results of therapeutic programs.

  • References16
  • Citations71


Mentioned in this Paper

Prostatic Neoplasms
Antineoplastic Agents
Laboratory Studies
Phosphoric Monoester Hydrolases
Malignant Bone Neoplasm
Serum Lactate Dehydrogenase Measurement
Stage IV Prostate Carcinoma
Prostate Carcinoma

About this Paper

Related Feeds


Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.